” The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling. evading growth suppressors, resisting… Continue reading
In the beginning of September, Dr Treon was invited to participate as a Guest Lecturer on Waldenstrom’s macroglobulinemia for participating Polish physicians and medical specialists. It was a overwhelming turnout and WM left a large impression in Eastern Europe. The… Continue reading
For those who are interested in learning about the current activity with Ibrutinib, please read the article below. This is the PR news release on the presentation in Lugano on Ibrutinib activity in relapsed/refractory WM which Dr. Treon had done a few weeks ago in Lugano, Switzerland during the Lymphoma Conference. Well over 3,000 physicians attended his lecture on this drug.
SUNNYVALE, Calif., June 20, 2013 /PRNewswire/ — Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today announced results of a study evaluating ibrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor in patients with Waldenstrom…
DEVELOPMENT OF A MOUSE GENETIC MODEL OF WALDENSTROM’S MACROGLOBULINEMIA
Background: Recently Whole Genome Sequencing (WGS) was performed on tumor cells from patients with Waldenstrom’s Macroglobulinemia (WM), an effort co-funded by the International Waldenstrom’s Macroglobulinemia Foundation (IWMF). Analysis of… Continue reading